T. Rowe Price Associates’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.22M | Buy |
|
|||||
|
2025
Q2 | $1.6M | Buy |
|
|||||
|
2025
Q1 | $1.98M | Sell |
|
|||||
|
2024
Q4 | $11.4M | Sell |
|
|||||
|
2024
Q3 | $10.9M | Sell |
|
|||||
|
2024
Q2 | $49M | Sell |
|
|||||
|
2024
Q1 | $145M | Sell |
|
|||||
|
2023
Q4 | $147M | Buy |
|
|||||
|
2023
Q3 | $67.8M | Sell |
|
|||||
|
2023
Q2 | $644M | Buy |
|
|||||
|
2023
Q1 | $303M | Buy |
|
|||||
|
2022
Q4 | $142M | Sell |
|
|||||
|
2022
Q3 | $229M | Sell |
|
|||||
|
2022
Q2 | $393M | Buy |
|
|||||
|
2022
Q1 | $401M | Buy |
|
|||||
|
2021
Q4 | $251M | Buy |
|
|||||
|
2021
Q3 | $158M | Sell |
|
|||||
|
2021
Q2 | $327M | Buy |
|
|||||
|
2021
Q1 | $156M | Buy |
|
|||||
|
2020
Q4 | $174M | Buy |
|
|||||
|
2020
Q3 | $89.9M | Sell |
|
|||||
|
2020
Q2 | $98.9M | Buy |
|
|||||
|
2020
Q1 | $33.5M | Buy |
|
|||||
|
2019
Q4 | $24.2M | Sell |
|
|||||
|
2019
Q3 | $21.1M | Buy |
|
|||||
|
2019
Q2 | $17.7M | Buy |
|
|||||
|
2019
Q1 | $13.3M | Sell |
|
|||||
|
2018
Q4 | $9.48M | Sell |
|
|||||
|
2018
Q3 | $16.2M | Sell |
|
|||||
|
2018
Q2 | $21.2M | Buy |
|